PerkinElmer has been granted a patent for a cell containing specific nucleic acid sequences related to adeno-associated virus (AAV) for gene expression control. The invention excludes AAV cap gene presence, enhancing gene therapy applications. GlobalData’s report on PerkinElmer gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights PerkinElmer Inc - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on PerkinElmer, Laboratory automation robots was a key innovation area identified from patents. PerkinElmer's grant share as of February 2024 was 58%. Grant share is based on the ratio of number of grants to total number of patents.

Cell comprising aav sequences without cap gene

Source: United States Patent and Trademark Office (USPTO). Credit: PerkinElmer Inc

A recently granted patent (Publication Number: US11926841B2) discloses a circular nucleic acid structure designed for conditional gene expression in cells. The nucleic acid comprises specific elements, including adeno-associated virus (AAV) sequences, promoters activated by helper polypeptides from Adenoviridae and Herpesviridae viruses, and transgenic coding sequences. Importantly, the circular nucleic acid does not contain an AAV cap gene, allowing for controlled expression of the transgenic coding sequence. The patent also covers methods for conditional gene expression, determining antiviral activity, detecting infectious viruses, quantifying virus levels, and identifying compounds with antiviral properties against Adenoviridae and Herpesviridae viruses.

Furthermore, the patent includes claims for a kit containing the described nucleic acid structure, helper polypeptides, polynucleotides, cells for transfection, and instructions for use. The methods outlined in the patent involve inducing gene expression through the activation of AAV promoters by helper polypeptides, determining antiviral activity of compounds, detecting and quantifying infectious viruses in samples, and identifying potential antiviral agents. The patent's innovative approach to conditional gene expression and antiviral research provides a valuable tool for the scientific community in studying and combating viruses from the Adenoviridae and Herpesviridae families.

To know more about GlobalData’s detailed insights on PerkinElmer, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.